JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
JW (Cayman) Therapeutics Co. Ltd. has announced a change in its auditor, with Deloitte Touche Tohmatsu replacing PricewaterhouseCoopers due to a disagreement over audit fees. The transition to Deloitte is expected to maintain audit quality without disrupting the company’s financial reporting for the year ending December 31, 2024. This strategic move underscores the company’s commitment to aligning with industry standards and ensuring shareholder interests.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.
